Cipla Sustainability

Sustainability

Our approach to responsible resource consumption, efforts to enhance access and affordability of medicines worldwide and strong financial growth, provide a robust foundation to build a responsible business.

8% Revenue CAGR over the last 5years
5.2% R&D Investment
₹ 21,763 Crores Revenue from Operations
cipla-sustainability

Manufacturing Highlights

Our investments in manufacturing capital include development of new drug delivery systems, facilitation of infrastructure supporting API and formulation developments and strengthening of platform technologies.

 

32.72 Billion
Tablets and capsules

 

144.20 Million
Aerosol pMDI

 

11.45 Million
Lyophilised injections

 

750 Million
Repsules

 

50.60 Million
Nasal sprays

 

51.20 Million
Oral liquids

 

2.50 Million
Form-fill seal eye-drops

 

 

COMMITTEES
OF BOARD
Learn More
MILESTONE
AWARDS
Learn More